[Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin].
The authors give a selection from the clinical-pharmacological and clinical studies of Grandaxin (tofizopam), an original Hungarian compound registered in 1976. Tofizopam, a 2,3-benzodiazepine derivative, differs from "classical" 1,4-benzodiazepines not only in chemical structure, but also in pharmacological and clinical-pharmacological properties. It is an anxiolytic without sedative-hypnotic, muscle relaxant and anticonvulsive effects. Tofizopam does not impair psychomotor and intellectual performance, like other benzodiazepines do, in the contrary, it has a mild stimulatory activity. It is potent in alleviating vegetative symptoms accompanying anxiety disorders. Tofizopam has a very low toxicity, mild side effects. The administration of tofizopam does not lead to physical or psychic dependence.
Szegó
J
J
EGIS Gyógyszergyár Rt., Budapest.
Somogyi
M
M
Papp
E
E
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D001569:Benzodiazepines / Q000627:therapeutic use*; D006801:Humans
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D001569:Benzodiazepines; C012582:tofisopam
Szemelvények a Grandaxin klinikai-farmakológiai és klinikai vizsgálataiból.